Monte Rosa Therapeutics Days Payable Outstanding
The Days Payable Outstanding (DPO) of Monte Rosa Therapeutics (GLUE) as of Oct 18, 2026 is 155.07. In the previous year, Days Payable Outstanding (DPO) was 773.73 — a change of -79.96% (lower).
Get this data via API
Financial Data API
Days Payable Outstanding
155.07
YoY
-79.96%
Last updated:
The Monte Rosa Therapeutics Days Payable Outstanding history
3 Years
10 Years
25 Years
Max
| YEAR | Days Payable Outstanding | YoY |
|---|---|---|
| 155.07 | -79.96% | |
| 773.73 | +18.27% | |
| 654.21 | +95.12% | |
| 335.28 | -70.14% | |
| 1,122.73 | -76.62% | |
| 4,802.77 | -70.35% | |
| 16,196.88 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Monte Rosa Therapeutics Stock analysis
Frequently Asked Questions about Monte Rosa Therapeutics stock
Days Payable Outstanding (DPO) of Monte Rosa Therapeutics is 155.07 in 2025.
Days Payable Outstanding (DPO) of Monte Rosa Therapeutics changed from 773.73 to 155.07, representing a -79.96% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.
DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Monte Rosa Therapeutics with sector peers and the industry average to assess whether it is attractive.
To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Profitability — Monte Rosa Therapeutics
All Key Metrics — Monte Rosa Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth